PharmAust Completes enrolment of second patient cohort in MND/ALS trial
- PharmAust (PAA) completes the enrolment of the second cohort of patients in its phase one and two clinical trial testing its monepantel (MPL) drug in MND and ALS
- The clinical study is assessing the tolerability, safety, pharmacokinetics and preliminary efficacy of oral MPL in people living with Motor Neurone Disease and Amyotrophic Lateral Sclerosis
- PAA says on completion of dosing the last patient of cohort two, an interim analysis will be carried out to look at potential indicator changes in biomarkers and pharmacodynamics
- The company will continue with MPL dose escalation for cohorts three and four to determine the ideal dosage for its phase two trial
- Shares in PAA are up 4.4 per cent and trading at 9.5 cents at 11:10 am AEDT
